发明名称 Mitochondrial Non-Coding RNAs for Predicting Disease Progression in Heart Failure and Myocardial Infarction Patients
摘要 The present invention relates to a method for predicting mortality of a test patient with chronic heart failure comprising based on detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8. The present invention also relates to a method for predicting cardiac remodeling after myocardial infarction in a test patient based on detecting the expression level of one or more lncRNAs selected from SEQ ID NOs 1 to 8.
申请公布号 US2017114409(A1) 申请公布日期 2017.04.27
申请号 US201515126927 申请日期 2015.03.18
申请人 Institut Pasteur de Lille (IPL) ;Medizinische Hochschule Hannover ;Institut National de la Santé et de la Recherche Médicale (INSERM) ;Université de Lille 2 (Lille 2) - University of Law and Health ;Centre Hospitalier Universitaire Lille (CHU) 发明人 THUM Thomas;KUMARSWAMY Regalla;PINET Florence;BAUTERS Christophe;DE GROOTE Pascal
分类号 C12Q1/68 主分类号 C12Q1/68
代理机构 代理人
主权项 1. A method for predicting mortality of a test patient with chronic heart failure comprising (a) detecting the expression level of one or more long non-coding RNAs (lncRNAs) selected from SEQ ID NOs 1 to 8 in a sample obtained from said test patient with chronic heart failure, (b) comparing said expression level of the one or more lncRNAs with the expression level of these one or more lncRNAs in a sample obtained from control patients with chronic heart failure, wherein the control patients were alive at least about three years after diagnosis of the chronic heart failure, and a greater than 2-fold overexpression of at least one of the one or more lncRNAs in the test patient's sample as compared to the control patient's sample is indicative of an enhanced likelihood for future cardiovascular death of the test patient; and/or (b′) comparing said expression level of the one or more lncRNAs with the expression level of these one or more lncRNAs in a sample obtained from control patients with chronic heart failure, wherein the control patients died from a cardiovascular event within about three years after diagnosis of chronic heart failure, and a greater than 2-fold underexpression of at least one of the one or more lncRNAs in the test patient's sample as compared to the control patient's sample is indicative of an enhanced likelihood for the long term survival of the test patient.
地址 Lille FR